Stem Cells in the Treatment of Refractory Chronic Migraines

Autologous adipose-derived stromal vascular fraction (SVF) shows promise for treating migraines. This treatment is rich in mesenchymal stromal cells. It may target neurogenic inflammation in migraine pathogenesis. The study involved adult patients with severe migraine-related disability. All participants failed botulinum toxin injections and at least three prophylactic drugs. The primary outcome measure was the change in MIDAS score at three months. Standard liposuction was performed to obtain adipose tissue. SVF was isolated from this tissue by centrifugation. Each patient received 8 to 10 mL of SVF, containing 2.5 to 8.6 million viable cells. Nine individuals participated, including one man and eight women. The average age was 48 years, and headaches lasted 16 years on average. After three months, the mean MIDAS score improved from 122 to 88. Seven out of nine patients had a decreased MIDAS score, while only two showed meaningful improvement. Clinical relevance: This research indicates that autologous SVF treatment may help chronic migraines effectively.